Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy

European Urology

Volumn 66, Issue 5, 2014, Pages 906-912

  Lughezzani, Giovanni ^a   Lazzeri, Massimo ^a   Haese, Alexander ^b   McNicholas, Thomas ^c   De La Taille, Alexandre ^d   Buffi, Nicolò Maria ^a   Fossati, Nicola ^a   Lista, Giuliana ^a   Larcher, Alessandro ^a   Abrate, Alberto ^a   Mistretta, Alessandro ^a   Bini, Vittorio ^e   Palou Redorta, Joan ^f   Graefen, Markus ^b   Guazzoni, Giorgio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c LISTER HOSPITAL   (United Kingdom)

^d INSERM   (France)

^e UNIVERSITY OF PERUGIA   (Italy)

^f FUNDACIÓ PUIGVERT   (Spain)

Author keywords

External validation; Nomogram; Prostate biopsy; Prostate cancer; Prostate Health Index

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; (-2)PRO-PROSTATE-SPECIFIC ANTIGEN, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CAUCASIAN; EUROPEAN; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOMOGRAM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; TERTIARY CARE CENTER; URINARY TRACT DISEASE ASSESSMENT; VALIDATION STUDY; BIOPSY; BLOOD; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; EPIDEMIOLOGY; ETHNOLOGY; EUROPE; HEALTH STATUS; HEALTH STATUS INDICATOR; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE TUMOR; REPRODUCIBILITY; RISK FACTOR; STATISTICAL MODEL;

AGED; BIOPSY; DECISION SUPPORT TECHNIQUES; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; KALLIKREINS; LOGISTIC MODELS; MALE; MIDDLE AGED; NOMOGRAMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TERTIARY CARE CENTERS;

EID: 84909963352     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.12.005     Document Type: Article

References (22)

1. E.A. Heijnsdijk, A. der Kinderen, E.M. Wever, G. Draisma, M.J. Roobol, H.J. de Koning Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer Br J Cancer 101 2009 1833 1838
2. W.J. Catalona, A.W. Partin, M.G. Sanda et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650 1655
3. G. Guazzoni, L. Nava, M. Lazzeri et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting Eur Urol 60 2011 214 222
4. F.H. Jansen, R.H. van Schaik, J. Kurstjens et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921 927
5. M. Lazzeri, A. Briganti, V. Scattoni et al. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy J Urol 188 2012 1137 1143
6. M. Lazzeri, A. Haese, A. de la Taille et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study Eur Urol 63 2013 986 994
7. S. Loeb, L.J. Sokoll, D.L. Broyles et al. Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration J Urol 189 2013 1702 1706
8. G. Lughezzani, M. Lazzeri, A. Larcher et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy J Urol 188 2012 1144 1150
9. G. Lughezzani, A. Briganti, P.I. Karakiewicz et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature Eur Urol 58 2010 687 700
10. M. Lazzeri, G. Lughezzani, A. Larcher et al. Reply to Sergey Tadtayev, Thomas A. McNicholas, and Gregory B. Boustead's letter to the editor re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer Eur Urol 61 2012 455 466 Eur Urol 2012; 62:e16-7
11. A. Semjonow, T. Köpke, E. Eltze, C. Darte Pre-analytical in-vitro stability of [-2]proPSA in blood and serum Clin Biochem 47 2010 926 928
12. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, L.L. Egevad The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242
13. E.R. DeLong, D.M. DeLong, D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
14. A.J. Vickers, E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565 574
15. S. Loeb Prostate Health Index (PHI): golden bullet or just another prostate cancer marker? Eur Urol 63 2013 995 996 discussion 996-7
16. X. Zhu, P.C. Albertsen, G.L. Andriole, M.J. Roobol, F.H. Schroder, A.J. Vickers Risk-based prostate cancer screening Eur Urol 61 2012 652 661
17. M. Auprich, A. Haese, J. Walz et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome Eur Urol 58 2010 727 732
18. F.K. Chun, A. de la Taille, H. van Poppel et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659 668
19. C. Stephan, H. Cammann, M. Bender et al. Internal validation of an artificial neural network for prostate biopsy outcome Int J Urol 17 2010 62 68
20. C.T. Nguyen, M.W. Kattan How to tell if a new marker improves prediction Eur Urol 60 2011 226 228 discussion 228-30
21. J. Hansen, M. Auprich, S.A. Ahyai et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay Eur Urol 63 2013 201 209
22. T. Rhodes, D.J. Jacobson, M.E. McGree et al. Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men J Urol 187 2012 92 96